| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 07/28/2011 | US20110182995 Medical and dental biomaterial and method of use for the same |
| 07/28/2011 | US20110182993 Film-form preparation |
| 07/28/2011 | US20110182992 Peptides and peptide mimetics to treat pathologies associated with eye disease |
| 07/28/2011 | US20110182981 Gonococcal vaccines |
| 07/28/2011 | US20110182978 Activated nitric oxide donors and methods of making and using thereof |
| 07/28/2011 | US20110182976 Lipoplex-patch based dna vaccine |
| 07/28/2011 | US20110182975 Method of conferring a protective immune response to norovirus |
| 07/28/2011 | US20110182974 Multimeric multiepitope influenza vaccines |
| 07/28/2011 | US20110182968 Interpenetrating polymer network hydrogel corneal prosthesis |
| 07/28/2011 | US20110182963 Osteoimplant and methods for making |
| 07/28/2011 | US20110182945 Semi-allogenic anti-tumour vaccine with hla haplo-identical antigen-presenting cells |
| 07/28/2011 | US20110182944 Method for inducing cell lysis with immunogenic portions of NY-ESO-1 protein |
| 07/28/2011 | US20110182943 Methods of immune or hematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer, cancer symptoms, or the symptoms of cancer treatments |
| 07/28/2011 | US20110182942 Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof |
| 07/28/2011 | US20110182941 Alphavirus and Alphavirus Replicon Particle Formulations and Methods |
| 07/28/2011 | US20110182940 Method for producing purified influenza virus antigen |
| 07/28/2011 | US20110182939 Vaccine Adjuvants |
| 07/28/2011 | US20110182938 Influenza nucleic acid molecules and vaccines made therefrom |
| 07/28/2011 | US20110182937 Dendritic Cell Vaccines |
| 07/28/2011 | US20110182936 Influenza hemagglutinin and neuraminidase variants |
| 07/28/2011 | US20110182935 Prevention and treatment of sub-clinical pcvd |
| 07/28/2011 | US20110182934 Immune system stimulating nutrition |
| 07/28/2011 | US20110182933 Modified vaccinia ankara virus variant |
| 07/28/2011 | US20110182932 Modified vaccinia ankara virus variant |
| 07/28/2011 | US20110182931 Immortal avian cell line and methods of use |
| 07/28/2011 | US20110182929 Multicomponent vaccine for malaria providing long-lasting immune responses against plasmodia |
| 07/28/2011 | US20110182928 Vaccine against amyloid folding intermediate |
| 07/28/2011 | US20110182927 Inhibitors of DNA Immunostimulatory Sequence Activity |
| 07/28/2011 | US20110182926 Minigene |
| 07/28/2011 | US20110182925 Ehrlichia canis DIVA (Differentiate Infected from Vaccinated Animals) |
| 07/28/2011 | US20110182924 Proteins with repetitive bacterial-ig-like (big) domains present in leptospira species |
| 07/28/2011 | US20110182923 Novel group b streptococcus antigens |
| 07/28/2011 | US20110182922 Peptides of il1 beta and tnf alpha and method of treatment using same |
| 07/28/2011 | US20110182921 Regulatory t cell epitopes, compositions and uses thereof |
| 07/28/2011 | US20110182920 Identification of a novel cysteine-rich cell penetrating peptide |
| 07/28/2011 | US20110182919 Immunoglobulin Chimeric Monomer-Dimer Hybrids |
| 07/28/2011 | US20110182918 Personalized drug treatment and smoking cessation kit and method |
| 07/28/2011 | US20110182917 Therapeutic or prophylactic agent for generalized pain syndrome |
| 07/28/2011 | US20110182916 Use of Agonists of Integrin Alpha 5 for Inducing the Osteogenic Differentiation of Mesenchymal Stem Cells |
| 07/28/2011 | US20110182915 Therapeutic agent or preventive agent for osteoarthritis |
| 07/28/2011 | US20110182914 Methods and compositions |
| 07/28/2011 | US20110182913 Anti fgf23 antibody and a pharmaceutical composition comprising the same |
| 07/28/2011 | US20110182912 Agents and methods for denervation |
| 07/28/2011 | US20110182911 Use of immobilized antagonists for enhancing growth factor containing bioimplant effectiveness |
| 07/28/2011 | US20110182910 Method of treating t cell mediated disorders |
| 07/28/2011 | US20110182909 Glufosfamide combination therapy |
| 07/28/2011 | US20110182908 Diagnostics and Therapeutics for Macular Degeneration-Related Disorders |
| 07/28/2011 | US20110182907 Anti-alpha-Enolase I Antibodies for Diagnosis and Treatment of alpha-Enolase I-Associated Diseases |
| 07/28/2011 | US20110182906 Fully human antibody to human tnf-alpha, molecular evolution and use thereof |
| 07/28/2011 | US20110182905 Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same |
| 07/28/2011 | US20110182904 Antibodies to bone morphogenic proteins and receptors therefor and methods for their use |
| 07/28/2011 | US20110182903 Novel soluble cd83 polypeptides, formulations and methods of use |
| 07/28/2011 | US20110182902 Recombination Sequence (RS) Rearrangement Frequency as a Measure of Central B Cell Tolerance |
| 07/28/2011 | US20110182901 Full length large t tumor antigen of merkel cell polyomavirus as a therapeutic target in merkel cell carcinoma |
| 07/28/2011 | US20110182900 Compositions and methods for treating coagulation related disorders |
| 07/28/2011 | US20110182899 Anti-glycoptrotein vi scfv fragment for treatment of thrombosis |
| 07/28/2011 | US20110182898 Immunosuppressive polypeptides and nucleic acids |
| 07/28/2011 | US20110182897 Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases |
| 07/28/2011 | US20110182896 CLOTTING FACTOR-Fc CHIMERIC PROTEINS TO TREAT HEMOPHILIA |
| 07/28/2011 | US20110182895 Antibody variants |
| 07/28/2011 | US20110182894 Methods of treating diabetes using IL-1beta antibodies |
| 07/28/2011 | US20110182893 Prevention and treatment of amyloidogenic diseases |
| 07/28/2011 | US20110182892 Methods to identify responsive patients |
| 07/28/2011 | US20110182891 Pharmaceutical dosage form comprising polymeric carrier composition |
| 07/28/2011 | US20110182890 Anti-pleiotrophin antibodies and methods of use thereof |
| 07/28/2011 | US20110182889 Compositions and methods for the treatment of natural killer cell related diseases |
| 07/28/2011 | US20110182888 Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor Modulator |
| 07/28/2011 | US20110182887 Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| 07/28/2011 | US20110182886 Compositions and methods for inhibiting tumor progression |
| 07/28/2011 | US20110182885 Formulations and treatments for well-being |
| 07/28/2011 | US20110182884 P-cadherin antibodies |
| 07/28/2011 | US20110182883 Novel gene disruptions, compositions and methods relating thereto |
| 07/28/2011 | US20110182882 Icotinib Hydrochloride, Synthesis, Crystalline Forms, Pharmaceutical Compositions, and Uses Thereof |
| 07/28/2011 | US20110182881 Signature and determinants associated with metastasis and methods of use thereof |
| 07/28/2011 | US20110182880 Combination Therapies Against Cancer |
| 07/28/2011 | US20110182879 Novel human transferase family members and uses thereof |
| 07/28/2011 | US20110182878 Anti-Ricin Antibody |
| 07/28/2011 | US20110182877 Sustained delivery of compstatin analogs from gels |
| 07/28/2011 | US20110182875 Novel class of therapeutic protein based molecules |
| 07/28/2011 | US20110182857 Delivery of Drugs to Mucosal Surfaces |
| 07/28/2011 | US20110182856 Inhibitors of serine proteases |
| 07/28/2011 | US20110182855 Conjugated biological molecules and their preparation |
| 07/28/2011 | US20110182851 Oxidized ldl specific antibody-fusion and conjugated proteins |
| 07/28/2011 | US20110182847 Use of tlr agonists and/or type 1 interferons to alleviate toxicity of tnf-r agonist therapeutic regimens |
| 07/28/2011 | US20110182829 Methods of stimulating immune response in virally infected individuals |
| 07/28/2011 | US20110182817 Antibody against calcified globule and use of the same |
| 07/28/2011 | US20110182809 Method of Promoting Neurogenesis |
| 07/28/2011 | US20110182806 Systems and methods for particle radiation enhanced delivery of therapy |
| 07/28/2011 | US20110180430 Adjuvanted influenza vaccines including cytokine-inducing agents |
| 07/28/2011 | CA2825137A1 Methods of treating or preventing periodontitis and diseases associated with periodontitis |
| 07/28/2011 | CA2787974A1 Immunogenic influenza composition |
| 07/28/2011 | CA2787783A1 Anti-ilt5 antibodies and ilt5-binding antibody fragments |
| 07/28/2011 | CA2787755A1 Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments |
| 07/28/2011 | CA2787753A1 Detection of early-stage pancreatic adenocarcinoma |
| 07/28/2011 | CA2787666A1 Targeted heterologous antigen presentation on calicivirus virus-like particles |
| 07/28/2011 | CA2787661A1 Vaccine vectors and methods of enhancing immune responses |
| 07/28/2011 | CA2787566A1 Anticoagulant antidotes |
| 07/28/2011 | CA2787184A1 Enterococcal cell wall components and antibacterial use thereof |
| 07/28/2011 | CA2787074A1 Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r) |
| 07/28/2011 | CA2786981A1 Stabilized antibody-containing liquid formulations |